A modified human prolactin molecule wherein the prolactin molecule comprises at least one mutation in a region selected from i) amino acids 41-57, ii) amino acids 94-110, and iii) amino acids 160-173; and wherein the at least one mutation is selected from deletions, replacements, and insertions. The modified prolactins are prolactin antagonists, and can be used in treating cancer, among other conditions.

 
Web www.patentalert.com

< Cross-linked networks from multifunctional hyperbranched polymers

< Thin nanometer-controlled polymer film gradient

> Knocking processing method in flat-type display device, and knocking processing method in flat-panel display device-use substrate

> Methods and compositions of novel triazine compounds

~ 00239